Scandmedical Soldk 040 Stock Net Income

K41 Stock   0.81  0.02  2.41%   
SCANDMEDICAL SOLDK 040 fundamentals help investors to digest information that contributes to SCANDMEDICAL SOLDK's financial success or failures. It also enables traders to predict the movement of SCANDMEDICAL Stock. The fundamental analysis module provides a way to measure SCANDMEDICAL SOLDK's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SCANDMEDICAL SOLDK stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

SCANDMEDICAL SOLDK 040 Company Net Income Analysis

SCANDMEDICAL SOLDK's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, SCANDMEDICAL SOLDK 040 reported net income of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Devices industry. The net income for all Germany stocks is 100.0% higher than that of the company.

SCANDMEDICAL Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SCANDMEDICAL SOLDK's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SCANDMEDICAL SOLDK could also be used in its relative valuation, which is a method of valuing SCANDMEDICAL SOLDK by comparing valuation metrics of similar companies.
SCANDMEDICAL SOLDK is currently under evaluation in net income category among its peers.

About SCANDMEDICAL SOLDK Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze SCANDMEDICAL SOLDK 040's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SCANDMEDICAL SOLDK using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SCANDMEDICAL SOLDK 040 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in SCANDMEDICAL Stock

SCANDMEDICAL SOLDK financial ratios help investors to determine whether SCANDMEDICAL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SCANDMEDICAL with respect to the benefits of owning SCANDMEDICAL SOLDK security.